<DOC>
	<DOCNO>NCT02829047</DOCNO>
	<brief_summary>The study prospective , multicenter , open-label , single-arm study , evaluate tolerability , safety efficacy Vibrant Capsule relieve constipation . One arm assess : Vibrant Capsule administer sequence one per day 2 day , follow one day without , one per day 2 day follow one day without , etc . ( 14 capsule 3 week ) . The study one interim analysis . Patients follow 2 week baseline period take Vibrant Capsule treatment period 6 week . Data report do electronic Case Report Form eDiary . During 2 week baseline , patient ask refrain take medication supplement relieve constipation . After 14 day patient return eligibility re-assessed . Patients train use base unit . Patients instruct complete simple patient eDiary day throughout duration study . After 3 week treatment , patient attend evaluation receive new capsule . A final visit take place end 6 week treatment period . Patients receive phone call twice per week patient compliance monitor 8 week study .</brief_summary>
	<brief_title>Tolerability , Safety Efficacy New Frequency Vibrant Capsule Administration</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Inclusion criterion 1 . Patients age 22 year old 2 . Patients Chronic Idiopathic Constipation accord Rome III criterion experience relief symptom available therapy ( osmotic stimulant laxative use least one month recommend dose ) 3 . Patients average less 3 Spontaneous Bowel Movements per week least 1 Spontaneous Bowel Movements per week 4 . Normal colonoscopy perform within 10 year prior study participation , unless patient le 50 year old without alarm sign and/or symptom 5 . Patient sign Informed Consent Form 6 . Female subject must negative urine pregnancy test must lactate prior receive study medication . For female childbearing potential , hormonal ( i.e. , oral , implantable , injectable ) singlebarrier method , doublebarrier method birth control must use throughout study . All female subject must reason inability bear child document medical record ; circumstance , urine pregnancy test necessary . Exclusion criteria 1 . History complicated/obstructive diverticular disease 2 . History intestinal colonic obstruction , suspect intestinal obstruction . 3 . History significant gastrointestinal disorder , include form inflammatory bowel disease gastrointestinal malignancy ( celiac disease accept subject treated remission ) 4 . History gastroparesis 5 . Use following medication : Medications may affect intestinal motility , prokinetics , antidepressant , antiParkinsonian medication , opiate , opioids , calciumchannel blocker , aluminum/magnesium hydroxide With exception antidepressant , thyroid hormonal replacement therapy , subject stable dose least 3 month prior enrollment . 6 . Clinical evidence significant respiratory , cardiovascular , renal , hepatic , biliary , endocrine , psychiatric neurologic disease . 7 . Presence cardiac pacemaker gastric electrical stimulator . 8 . History , current eating disorder , anorexia , bulimia , compulsory overeating . 9 . Diagnosis megarectum colon , congenital anorectal malformation , clinically significant rectocele , history intestinal resection ( exception appendectomy , cholecystectomy inguinal hernia repair ) , history bariatric surgery evidence structural abnormality gastrointestinal tract might affect transit 10 . History Zenker 's diverticulum , dysphagia , Barrett 's esophagus , esophageal stricture achalasia 11 . Chronic use nonsteroidal antiinflammatory drug : chronic use define take full dose nonsteroidal antiinflammatory drug three time week least six month . Patients cardiac dos aspirin may enrol study 12 . Patients pelvic floor dysfunction/defecatory disorder , base patient history 13 . Participation another clinical study within one month prior screen . 14 . Women pregnant lactate 15 . Use medication constipation relief study , except rescue medication , indicate study rule 16 . Inability use electronic daily Diary ( computer , phone application , tablet electronic device ) report bowel movement , symptom medication usage 17 . Any condition opinion investigator may adversely affect safety patient would limit patient 's ability complete study</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>